Answers are grounded in this paper and cite their sources.
Uterine serous cancer (USC) comprises around 10% of all uterine cancers. However, USC accounts for approximately 40% of uterine cancer deaths, which is attributed to tumor aggressiveness and limited effective treatment. Galectin 3 (Gal3) has been implicated in promoting aggressive features in some malignancies. However, Gal3's role in promoting USC pathology is lacking.
No takes yet. Share an insight, caveat, or question.
Matoba et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: